Eli Lilly bets up to 2.75 billion on Insilico Medicine AI platform Pharma.AI, signaling Big Pharma shift to AI led drug discovery and global R and D partnerships.
The idea that artificial intelligence could disrupt white-collar work is no longer new. It has already reshaped industries from algorithmic trading on Wall Street to content creation in Hollywood. And now it’s coming for one of the most complex and high-stakes domains of all – drug discovery.
Continue Reading with
Continue Reading with
CNBC-TV18 Access Membership
Priority Access and Networking: CNBC-TV18’s flagship events
Interaction with CNBC-TV18’s journalists
Webinars & LIVE Q&As with India Inc. Leaders
Exclusive CNBC-TV18 studio & newsroom tours
Premium business insights, expert opinions & analysis
Curated lifestyle privileges & offers




